Coronavirus Disease (COVID-19) pandemic {#sec0001}
=======================================

On March 11^th^ 2020, WHO (World Health Organization) declared Coronavirus Disease (COVID-19) pandemic **\[** [@bib0001] **\]**. Just three mouth ago (December 2019), the first cases of unexplained severe acute respiratory syndrome and pneumonia were reported in the province of Hubei (China) **\[** [@bib0002] **\]** and subsequently this respiratory syndrome was associated with infection of SARS-CoV-2 (before named 2019-nCoV) infection **\[** [@bib0003] **\]**, a novel human coronavirus belonging β-coronavirus cluster which also includes SARS-CoV and MERS-CoV viruses **\[** [@bib0003] **\]**. Currently, in the first week of May, approximately 4000000 individuals have been infected, 290000 subjects have dead in 208 countries **\[** [@bib0001] **\]**. These numbers highlight the global severity of this epidemic for health and economic worldwide development.

The cornerstone of COVID-19 pandemic management is the early detection of positive patients and their isolation to prevent other further infections, considering that SARS-CoV-2 spreads through respiratory droplets. The clinical strategy for COVID-19 treatment is represented by symptomatic treatments, as no specific protocols, antiviral drugs or vaccine have been just developed **\[** [@bib0004] **\]**.

Epidemiological studies indicate that the elderly and above all subjects affected by metabolic syndrome, diabetes and/or cardiovascular diseases (especially hypertension) are more susceptible to SARS-CoV-2 infection as highlighting from an increased symptoms severity, disease rate progression and lastly mortality **\[** [@bib0002] **,** [@bib0005] **\]**.

Given the high number of infected people who need intensive care and the ineffectiveness/aspecificity of current adopted therapies, many countries are now committed to limiting SARS-CoV-2 exponential growth of making extraordinary decisions, including the 'lock-down' of some regions or entire countries with a severe economic impact **\[** [@bib0006] **\]**.

Hoping to contain COVID-19 pandemic as soon as possible and until vaccine development, the problem of higher SARS-CoV-2-associated risk and mortality in frail subpopulation, (diabetics and subjects with metabolic syndrome or cardiovascular diseases) remains. Some authors have strongly advised to implement blood glucose management in diabetic patients, using online service and avoiding person-to-person contact **\[** [@bib0007] **\]**. Others have suggested a tighter nutritional control to avoid malnutrition conditions **\[** [@bib0008] **\]**.

However, to protect frail subjects, it is necessary to investigate the mechanisms involved in the aberrant immune response triggered by SARS-Cov-2 and to identify possible therapeutic targets to counteract it.

Aberrant immune inflammatory response induction and SARS-CoV-2 {#sec0002}
==============================================================

SARS-CoV-2 activates intracellular stress pathways, inducing and taking advantage of aberrant response by host innate and adaptive immune system, which plays a crucial role in causing fatal pneumonia and death **\[** [@bib0001] **\]**.

SARS-CoV-2, as SARS-CoV, enters the host target cells by binding to ACE2 protein **\[** [@bib0009] **\]**.

Inflammatory process begins after the interaction of SARS-CoV-2 with toll-like receptor (TLR), whose activation triggers a sequence of responses from the host cell, which lead to interleukins (ILs) synthesis **\[** [@bib0010] **\]** and inflammasome activation **\[** [@bib0011] **\]**.

Previous robust data testify how SARS-CoV, whose sequence homology with SARS-CoV-2 is 96% **\[** [@bib0012] **\]**, interacts with Nod-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome indicating NLRP3 as coronavirus inflammatory target **\[** [@bib0013] **,** [@bib0014] **\]**.

NLRP3 inflammasome is a multiprotein complex consisting of NOD-like receptor NLRP3, ASC (Adaptor Protein Apoptosis-Associated Speck-Like Protein Containing CARD adapter) molecule and pro-caspase 1 effector molecule **\[** [@bib0015] **\]**. Following an inflammatory insult, the assembly of these three complexes induces caspase-1 activation by cleavage of pro-caspase-1 and, then, pro-IL-1 and pro-IL-18 conversion in their active forms IL-1 and IL-18 **\[** [@bib0015] **-** [@bib0018] **\]**. NLRP3 inflammasome is associated with various autoimmune, inflammatory and metabolic diseases and its formation is responsible for pyroptosis due to the loss of the ionic gradient following the formation of pores on the cell membrane **\[** [@bib0016] **\]**.

NLRP3 activation requires two steps, both generated by stressful conditions **\[** [@bib0015] **,** [@bib0017] **,** [@bib0018] **\]**: first transcriptional activation of inflammasome related proteins (including NLRP3, proIL-1β and proIL-18) and then their subsequent assembly and activation.

The priming step occurs following NF-kB induction enhancing by interaction between several microbial molecules or endogenous cytokines with different receptors, including TLRs **\[** [@bib0019] **\]**: the binding of lipopolysaccharide (LPS), the major structural component of Gram-negative bacteria membrane**,** to TLR4 receptor represents a strong stimulus for NF-kB activation **\[** [@bib0020] **\]**. LPS-TLR4 binding, enhancing JNK and IKK intracellular signaling, leads to NF-kB activation through the dissociation of its inhibitor ([Figure 1](#fig0001){ref-type="fig"} ). This process culminates in NF-kB translocation into the nucleus and the consequent mRNA expression of all inflammasome subunits **\[** [@bib0021] **\]**.Figure 1**Possibly molecular mechanisms involved in aberrant inflammatory response to SARS-CoV-2 in frail patients** The binding of SARS-CoV-2 to ACE2 and its interaction with intracellular TLRs triggers a sequence of responses which leads to NF-bK activation and ILs synthesis. Host cell inflammation could be exacerbated by NLRP3 inflammasome activation and by pro-inflammatory cytokines production.NLRP3 inflammasome activation requires two steps generated by stressful conditions: the transcription of NLRP3 and ASC, pro-caspase-1 and their assembly and activation. The first step is consequent to NF-kB activation and translocation into the nucleus, stimulated by LPS-TLR4 binding through JNK and IKK intracellular signaling. The second step is induced by an abnormal mitochondrial ROS production, or by PAMPs, DAMPs and MAMPs stimuli related to gut dysbiosis. Moreover, the K^+^ outflow, due to ATP extracellular stimulus, or intracellular and cytosolic Ca^2+^ fluxes imbalance induces NLRP3 inflammasome assembly.NLRP3 activation is also regulated by AngII overexpression stimulated by LPS-TRL4 interaction and by gut dysbiosis-derived metabolite TMAO.Figure 1:

Recent data suggest that TLR4 receptor could play an important role also in viral infection immune response **\[** [@bib0021] **\]**: TLR4 over-stimulation is associated with an excessive inflammatory response and an unfavourable outcome of viral infection **\[** [@bib0022] **\]**. Olejnik J et al have demonstrated that TLR4 signalling inhibition reduces excessive pro-inflammatory response during Ebola virus infection **\[** [@bib0023] **\]**. In the same manner, TLR4 and LPS antagonists, which inhibiting the LPS-TLR4 binding, prevent receptor activation and significantly reduce the inflammatory state during Respiratory syncytial virus infection **\[** [@bib0024] **\]**. On the other hand, other authors have suggested that a low degree of TLR4 activation could have positive effects in establishing a protective immune response during viral infection and that TLR4^(-\ /\ -)^ mice are more sensitive to SARS-CoV compared to wild-type mice **\[** [@bib0025] **\]**. These data suggest that TLR4 activation degree is crucial in SARS-CoV infection: TLR4 over activation is associated with a poor prognosis. In this context, it is conceivable to believe that concomitant pathologies that excessively activate TLR4 could aggravate COVID-19 condition.

The second step of NLRP3 activation is represented by inflammasome subunits (NLRP3, ASC, pro-caspase 1) assembly, that is essential for caspase-1 supply and IL-1β and IL-18 production and secretion **\[** [@bib0015] **,** [@bib0026] **\].** This process is stimulated by different cellular stress conditions including ATP extracellular stimulus, that determines an outflow of K^+^ and membrane pores formation, or fluxes of intracellular and cytosolic Ca^2+^ (i.e. mitochondrial dysfunction due to Ca^2+^ overload) **\[** [@bib0018] **,** [@bib0027] **\]**. In the same way, an aberrant ROS production, pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) induce NLRP3 assembly **\[** [@bib0028] **\]** ([Figure 1](#fig0001){ref-type="fig"}).

To note, NLRP3 is also regulated by angiotensin II (AngII) **\[** [@bib0029] **\]**, a key hormone of renin-angiotensin system (RAS) involved in blood pressure regulation **\[** [@bib0030] **\]**. AngII, is strongly responsible for oxidative stress induction, inflammation and fibrosis process characterizing numerous diseases, including hypertension **\[** [@bib0031] **\]** and insulin-resistance **\[** [@bib0032] **\]**. These metabolic alterations predispose to metabolic syndrome and T2DM, which are associated with an increased risk of heart diseases and lung dysfunction **\[** [@bib0033] **,** [@bib0034] **\]**. Numerous studies have shown that AngII stimulates NLRP3 inflammasome promoting proinflammatory cytokines expression **\[** [@bib0031] **,** [@bib0035] **\]**. Interestingly, some authors have observed that LPS-TLR4 interaction is involved in AngII overexpression and consequently in NLRP3/NF-kB activation **\[** [@bib0036] **,** [@bib0037] **\]** ([Figure 1](#fig0001){ref-type="fig"}).

The above leads to deduce that pathogenetic stimuli, capable to increase NLRP3 activation, contribute to worsening the pro-inflammatory conditions trigged by SARS-CoV-2.

Recent accumulating evidence indicates that Ang-(1--7), derived from AngII degradation by ACE2 enzyme, is a counter-regulator for the AngII pro‐oxidative and NLRP3 inflammasome activation **\[** [@bib0038] **\]**. Different authors have demonstrated that an increased Ang-(1-7) level, by exogenous administration or by molecules enhancing Ang-(1-7) signaling, improves lung pathology in mice models [@bib0039], [@bib0040], [@bib0041]. It is important to note that cardiovascular and pulmonary health is closely related to AngII/Ang-(1-7) axis controlled by ACE2, SARS-2-CoV-2 functional receptor, and in COVID-19 patients ACE2/Ang-(1-7) pathway is down regulated **\[** [@bib0042] **\]**. Probably in COVID-19 patients affected by metabolic syndrome, diabetes or cardiovascular diseases SARS-CoV-2 exacerbates ACE2/Ang-(1-7) axis alteration worsens the inflammation state and multi-organ damages ([Figure 1](#fig0001){ref-type="fig"}).

During the first weeks of pandemic, some authors and social media have speculated that ACE inhibitors and AngII type 1 (AT1) receptor blockers (ARBs), used for treatment of hypertension, facilitates SARS-CoV-2 infection by increasing ACE2 expression. The data, supporting this hypothesis, are conflicting.

Although ACE and ACE2 enzymes are highly homologous, they catalyse different reaction of the renin-angiotensin system and ACE inhibitors are not able to inhibit ACE2. Moreover, different works reported that ARBs increase ACE2 expression, but ARBs action is dose-related and tissue-specific. Inappropriate information about these antihypertensives caused stress and anxiety in patients and some of them have discontinued treatment, probably aggravating their condition.

Currently, ACE inhibitors or ARBs correlation with SARS-CoV-2 severe illness is not clinically proven. Indeed, as mentioned above, elevated Ang-(1--7) probably has a protective pulmonary action. For this reason, therapy with renin-angiotensin system blockers should not be withdrawn and should not be modified to prevent SARS-CoV-2 infection **\[** [@bib0043]--[@bib0044] **\]**.

Possible link between gut dysbiosis and Covid-19 severe illness {#sec0003}
===============================================================

Gut microbiome has received growing attention over the last decades and accumulating data have showed how gut alterations are associated with physiological and pathological condition \[[@bib0045],[@bib0046],[@bib0047]\]. In particular, in diabetic and heart disease patients, gut microbiota is characterized by a decrease in microbiological diversity associated with an altered ratio between Firmicutes (F) and Bacteroidetes (B), the two principal phyla in intestinal microflora, in favour of F \[[@bib0048],[@bib0049],[@bib0050]\].

It is well established that altered F/B ratio decreases intestinal permeability promoting PAMPs, DAMPs and MAMPs (microbial-associated molecular patterns) productions and contributes to the pro-inflammatory state **\[** [@bib0051] **\]**.

Moreover, gut dysbiosis is associated with an increased level of trimethylamine N-oxide (TMAO), gut microbiota-derived metabolite, processed after choline and L-carnitine ingestion **\[** [@bib0052] **-** [@bib0053] **\]**. This molecule has been receiving interest as a mediator in systemic inflammation and atherosclerosis condition **\[** [@bib0054]--[@bib0056] **\]**. Both observational and experimental studies suggest that TMAO causes endothelial inflammatory injury **\[** [@bib0055] **,** [@bib0056] **\]**.

Remarkably, recent studies have shown that TMAO recruits NLRP3 inflammasome, by activating NF-kB and ROS signaling, induces pro-inflammatory cytokines release and promotes over-inflammatory condition **\[** [@bib0057] **,** [@bib0058] **\]**. Therefore, high TMAO levels are correlated with an abnormal inflammation condition that could be exacerbated by SARS-CoV-2 infection ([Figure 1](#fig0001){ref-type="fig"}).

However, other elements seem to be involved.

LPS-TLR4 interaction **\[** [@bib0019] **-** [@bib0020] **\]** plays a role in the pathogenesis of insulin resistance **\[** [@bib0059] **-** [@bib0060] **\]**: higher levels of plasma LPS concentration were found in obese, T2DM and elderly patients compared to healthy subjects **\[** [@bib0060] **\]**. LPS-TLR4 binding not only triggers inflammatory condition but also inhibits insulin-stimulated IRS1 phosphorylation and impairs glucose homeostasis control **\[** [@bib0061] **\]**. To confirm LPS-TLR4 role in insulin resistance, recent evidence has revealed that NLRP3 activation represents an essential mechanism in metabolic inflammation and insulin resistance induction **\[** [@bib0061] **\]** and its inhibition could prevent ischemic stroke in diabetic patients **\[** [@bib0062] **\]**. Furthermore, as previous reported, LPS-TLR4 axis increases AngII overexpression contributing to destroy ACE2/Ang-(1-7) balance **\[** [@bib0036] **,** [@bib0037] **\]**.

Of note, inflammation induced by gut microbiota altered composition represents an important mediator in cardiometabolic and diabetic pathogenesis and could contribute to aggravate SARS-CoV-2 infection in frail patients.

As further support of this hypothesis, high plasma LPS levels are correlated with lung diseases and IL-6 overproduction. Several works have shown that LPS, promoting IL-6 production, is strongly involved in lung pathologies accelerating neutrophil recruitment and cell infiltration **\[** [@bib0063] **,** [@bib0064] **\]**. Chen L et al have highlighted IL-6 important pathophysiological role in COVID-19 disease proposing IL-6 serum level as a biomarker for SARS-CoV-2 prognosis: IL-6 high levels are associated with poor prognosis **\[** [@bib0065] **\]**. Different groups have proposed to counteract IL-6 overproduction and Tocilizumab, an IL-6 inhibitor usually used in rheumatoid arthritis treatment, has already been administered to COVID-19 Chinese patients. In Italy, a clinical trial has started to evaluate Tocilizumab safety and efficacy and the US Food and Drug Administration (FDA) has formally approved Tocilizumab phase 3 trial in severely ill COVID-19 subjects **\[** [@bib0066] **,** [@bib0067] **\]**.

Recently, different authors have emphasized the important relationship between the gut microbiome and the lung assuming a gut-lung axis. The gut microbiome is crucial for immune homeostasis and above all pulmonary innate immunity against infections. In mice altered microbiota composition, induced by treatment with antibiotic cocktails, is associated with an ineffective T-, and B-cell immunity following influenza virus infection. These animals displayed an impaired capacity to reduce viral replication and consequently an improved morbidity and mortality **\[** [@bib0068] **,** [@bib0069] **\]**.

Nutritional strategies aimed at improving gut dysbiosis and reducing low chronic inflammation state {#sec0004}
===================================================================================================

Intestinal dysbiosis could contribute to the aberrant inflammatory response triggered by SARS-CoV-2. Nutraceutical strategies aimed at restoring eubiosis condition could represent a valid adjuvant intervention for COVID-19 management.

To reduce TMAO production, a limitation of the ingestion of choline and carnitine, from which TMAO derives, could be foreseen **\[** [@bib0070] **\]**, but these molecules are essential to maintain healthy state. Choline has an structural role and is a neurotransmitters precursor; while several groups, including ours, have demonstrated that L-carnitine improves musculoskeletal function **\[** [@bib0071] **,** [@bib0072] **\]** and has an crucial anti-oxidant action on heart, in particular during myocardial infarction **\[** [@bib0073] **\]**.

Alternatively, the use of prebiotics and probiotics could be convenient to decrease TMAO production.

Martin FP et al have demonstrated that Lactobacillus paracasei ingestion counteracts TMAO synthesis **\[** [@bib0074] **\]**. Moreover, Qui L et al have studied the beneficial effect of Enterobacter aerogenes ZDY01 and Lactobacillus plantarum ZDY04 administration on TMAO levels **\[** [@bib0075] **,** [@bib0076] **\]** while some authors have obtained encouraging results promoting gut colonization with methanogenic archaea **\[** [@bib0077] **\]**.

In addition, resveratrol **\[** [@bib0078] **\]** and berberine **\[** [@bib0079] **\]** nutraceutical supplementation seems able to modulate gut composition decreasing TMAO production. Moreover, diet enriched with polyphenols ameliorates metabolic syndrome enhancing gut eubiosis. In particular, Roopchand DE et al have studied the effect of Concord grape polyphenols (GP) on high-fat diet observing that this nutraceutical intervention attenuates the production of inflammatory markers, including IL-6 and LPS. Moreover, GP modifies F/B ratio decreasing the growth of Firmicutes and increasing Akkermansia muciniphila bacteria **\[** [@bib0080] **\]**.

The positive role of Akkermansia muciniphila on metabolic syndrome and immune diseases has been well investigated in numerous animal models and human works **\[** [@bib0081] **\]**. In obese mice, the administration of Akkermansia muciniphila decreases hepatic lipid accumulation, IL-6 expression and ameliorates the altered ratio F/B **\[** [@bib0082] **\]**.

Several studies have proved that inulin, an important soluble dietary fiber, or oligofructose consumption are involved in LPS reduction and in maintenance of gut barrier integrity.

Zhang Q et al have demonstrated that inulin decreases Desulfovibrio abundance, reducing LPS and IL-6 levels in mice models **\[** [@bib0083] **,** [@bib0084] **\]**. This inulin action is replicated in human clinical trials **\[** [@bib0085] **,** [@bib0086] **\]**.

In addition, oligofructose consumption with/without inulin-enrichment exerts a positive action on gut dysbiosis and inflammation. Parnell JA has observed that 12 weeks of oligofructose supplementation induces a significant plasma LPS reduction in overweight and obese adults **\[** [@bib0087] **\]**. In addition, oligofructose-enriched inulin treatment alleviates metabolic endotoxemia in diabetic women **\[** [@bib0088] **\]**. It has been reported that oligofructose intake rises the amount of Roseburia in the intestinal gut. Different works have demostrated that Roseburia increasing differentiation of regulatory T cells inhibited intestinal inflammation **\[** [@bib0089] **\]**.

Moreover, probiotic and prebiotic food compounds can selectively modify gut microbial community enhancing growth of health-promoting bacteria, i.e. Lactobacillus spp., Bifidobacterium breve and Bacteroides‐Prevotella spp.. Recently Milajerdi A et al have performed an interesting meta-analysis observing how probiotic supplementation significantly reduces several cytokines production, including IL-6 **\[** [@bib0090] **\]**.

In obese mice, Lactobacillus rhamnosus LS-8 and Lactobacillus crustorum MN047 supplementation ameliorates inflammatory state and gut dysbiosis, reducing Bacteroides and Desulfovibrio bacteria and increasing Lactobacillus and Bifidobacterium population **\[** [@bib0091] **\]**.

Supplementation with Bifidobacterium animalis subsp. lactis V9 inhibits the hepatic expression of TLR4 and NLRP3 reducing the secretion of inflammatory cytokines (IL-6, IL-1β, and TNF-α) **\[** [@bib0092] **\]**.

Clinical trial, performed by Ried K et al. for 3 months, has established that Kyolic-aged-garlic-extract has an important anti-hypertensive action but above all decreases TNF-α and IL-6 and improved gut diversity increasing immune stimulating bacteria, Lactobacillus and Clostridia species **\[** [@bib0093] **\]**.

Accumulated data confirm the beneficial effects of probiotic/prebiotic oral supplementation on inflammatory condition. Many of these compounds are already marketed and it may be possible to develop personalized dietary regimens for subjects most vulnerable to SARS-CoV-2 **\[** [@bib0094] **,** [@bib0095] **\].**

Conclusion {#sec0005}
==========

Overall, clinical data exists that patients with obesity, hypertension, diabetes and in general with metabolic syndrome (frail patients) are at higher risk for COVID-19. As known, the interconnection between these pathologies and gut microbiota composition promotes an aberrant secretion of bacterial products, including TMAO and LPS. LPS binding to TRL4 induced a low-grade inflammation state. Data reported in literature suggested how SARS-CoV-2 interacting with TRL activates NLRP3 inflammasome, that can also be activated by TMAO ([Figure 1](#fig0001){ref-type="fig"}), worsening the host cellular pro-inflammatory microenvironment.

Pending the development of specific drugs or vaccine, effective strategies to ensure good health for patients with metabolic syndrome must be identified. It is well established that modulation of the microbiome through diet or probiotics/prebiotics ameliorates inflammation state. In this work, we reviewed some nutritional interventions focusing on gut microbiota aimed at improving low-grade inflammation condition. Currently, consumption of probiotics/prebiotics, polyphenols, or oligofructose/inulin counteracts gut dysbiosis and ameliorated inflammation state.

Future advances on the knowledge of COVID-19 molecular mechanisms would lead to an improved understanding of interactions between SARS-CoV-2 and gut microbiota. In perspective, after microbiota analyses, a novel personalized nutritional approach will be developed to restore a healthy gut microbiota and avoid SARS-CoV-2-induced exacerbated inflammation in frail patients.
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